The Rogosin Institute
|This article needs additional citations for verification. (June 2009)|
The Rogosin Institute is an independent not-for-profit treatment and research center that has been providing care to patients for fifty two years. Affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical College, The Rogosin Institute provides care for patients with kidney disease, including dialysis and transplantation, lipid disorders/high cholesterol, and hypertension. The Institute is spearheading research programs for cancer and diabetes. The Rogosin Institute has facilities throughout New York City.
The Rogosin Institute, pioneers in the treatment of kidney failure and kidney transplantation through hemodialysis, has a reputation for performing procedures at the forefront of medical technology.
In 1957, the Rogosin team performed the first hemodialysis in the New York metropolitan area as a treatment for kidney failure. In 1962, the unit became known as the Renal Laboratory and moved to the New York Hospital-Cornell Medical Center. There, it expanded to the Rogosin Renal Laboratories, named in honor of [[Israel Rogosin]] (1886-1971), an American textile industrialist and philanthropist who was a generous benefactor of the New York Hospital-Cornell Medical Center. In 1963, The Rogosin Institute performed the first kidney transplant in the New York area.
With expansion into research and treatment of cardiovascular disease and cancer, The Rogosin Institute was founded as an independent corporate entity in 1983. In 1988, many of The Rogosin Institute’s facilities were brought together in The New York Hospital’s Helmsley Medical Tower at 70th Street and York Avenue, where The Rogosin Institute currently resides. The historical administrative records of the Institute are housed in the Medical Center Archives of NewYork-Presbyterian/Weill Cornell.
Kidney Disease - Dialysis
Since performing the first dialysis for the treatment of end stage kidney disease in the New York City metropolitan area, The Rogosin Institute has grown to supervising 80,000 dialyses each year. In addition to traditional hemodialysis, The Rogosin Institute offers its patients a number of options, including peritoneal dialysis and home nocturnal hemodialysis. The Rogosin Institute dialysis centers are located in Manhattan, Brooklyn, and Queens, New York.
Kidney Disease - Transplantation
The Rogosin Institute is a pioneer in the implementation of technologies that make kidney transplantation more accessible and successful, such as programs for highly sensitized transplant recipients and the use of steroid-free protocols. The Rogosin Institute has also expanded the availability of kidney transplantation by developing de-sensitizing programs for incompatible donors and donor exchange programs. Since performing the first kidney transplant in the New York metropolitan area in 1963, The Rogosin Institute has completed more than 3,000 successful transplants.
Cholesterol and Lipid Disorders
The Rogosin Institute Comprehensive Lipid Control Center (CLCC) is a research and treatment centers focused on cholesterol control. The CLCC treats adults and children with cholesterol and triglyceride disorders and provides a full range of diagnostic and individualized treatment plans. A leader in research for treatment of lipid disorders, The Rogosin Institute pioneered clinical research of LDL-apheresis in the early 1980s, which led to the adoption of LDL-apheresis as a procedure to treat patients with the genetic form of extremely high cholesterol.
Uncontrolled hypertension can damage many organs, including kidneys. The Rogosin Institute physicians treat hypertension for individuals with hypertension alone and patients with hypertension and kidney disease.
Investigators at The Rogosin Institute are involved in early clinical testing of possible treatments for cancer and diabetes. The Institute’s cancer research is based on the principle that all living cells have some built-in control of their growth and development. The research involves using encapsulated cancer cells that release substances that tell cancer cells to slow or stop their growth. Responses in tumors and improved quality of life for patients have been observed and additional studies are underway.
Diabetes research at The Rogosin Institute was stimulated by the fact that diabetes is the largest cause of end-stage kidney disease. Research began in 1987 on a process that replaces cells that produce insulin in the body (beta cells in the islets of the pancreas) in order to reverse insulin-dependent diabetes. The research involves a unique encapsulation of islet cells and early testing is underway.
- Official website
- The Rogosin Institute on Twitter